LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

81.73 0.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

80.94

Max

81.86

Galvenie mērījumi
By Trading Economics
Ienākumi	-252M -129M
Pārdošana	-295M 157M
EPS	-0.613
Peļņas marža	-82.062
Darbinieki	1,069
EBITDA	-245M -94M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+3.24% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.6B 13B
Iepriekšējā atvēršanas cena	81.51
Iepriekšējā slēgšanas cena	81.73

Ziņu noskaņojums

By Acuity

34%

66%

85 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. dec. 21:08 UTC

Iegādes, apvienošanās, pārņemšana

Meta Platforms Buys AI-Device Maker Limitless

2025. g. 5. dec. 19:39 UTC

Galvenie tirgus virzītāji

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

2025. g. 5. dec. 19:17 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

2025. g. 6. dec. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

2025. g. 6. dec. 10:30 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

2025. g. 6. dec. 02:38 UTC

Iegādes, apvienošanās, pārņemšana

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

2025. g. 5. dec. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

2025. g. 5. dec. 21:50 UTC

Tirgus saruna

Peļņas

Financial Services Roundup: Market Talk

2025. g. 5. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

2025. g. 5. dec. 21:36 UTC

Tirgus saruna

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

2025. g. 5. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

2025. g. 5. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

2025. g. 5. dec. 21:12 UTC

Tirgus saruna

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

2025. g. 5. dec. 21:03 UTC

Tirgus saruna

Peļņas

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

2025. g. 5. dec. 21:01 UTC

Tirgus saruna

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

2025. g. 5. dec. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

2025. g. 5. dec. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

2025. g. 5. dec. 20:42 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

2025. g. 5. dec. 20:01 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

2025. g. 5. dec. 19:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 5. dec. 19:44 UTC

Tirgus saruna

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

2025. g. 5. dec. 19:39 UTC

Tirgus saruna

Silver Climbs to a New Record High -- Market Talk

2025. g. 5. dec. 19:31 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025. g. 5. dec. 18:30 UTC

Tirgus saruna

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

2025. g. 5. dec. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025. g. 5. dec. 18:24 UTC

Iegādes, apvienošanās, pārņemšana

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

2025. g. 5. dec. 18:20 UTC

Tirgus saruna

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

2025. g. 5. dec. 18:11 UTC

Tirgus saruna

The Tale of Two Canadian Employment Indicators -- Market Talk

2025. g. 5. dec. 17:48 UTC

Tirgus saruna

Canadian Youth Unemployment Rate Cools -- Market Talk

2025. g. 5. dec. 17:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

3.24% augšup

Prognoze 12 mēnešiem

Vidējais 84.33 USD 3.24%

Augstākais 110 USD

Zemākais 65 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

85 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.